| Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)
|
Authors: Lena J. Gamble, Anton V. Borovjagin, Qiana L. Matthews |
Affiliations:
Division of Human Gene Therapy, Departments of Medicine, Pathology, Surgery, Obstetrics and Gynecology, The Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL, USA
|
Doi: 10.3892/etm_00000037 |
Pages: 233-240 |
Abstract:
The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.
|
|
|
|
|
